3180 related articles for article (PubMed ID: 30786725)
1. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
2. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ
Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
[TBL] [Abstract][Full Text] [Related]
6. Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis.
Gu X; Jiang S; Yang Y; Li W
Diabetol Metab Syndr; 2024 Jan; 16(1):14. PubMed ID: 38212831
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
8. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U
Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180
[TBL] [Abstract][Full Text] [Related]
9. A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials: Implications for practice.
Battise DM; Olin JL
J Am Assoc Nurse Pract; 2021 Mar; 33(12):1139-1147. PubMed ID: 33105320
[TBL] [Abstract][Full Text] [Related]
10. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
[TBL] [Abstract][Full Text] [Related]
11. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Patel SM; Kang YM; Im K; Neuen BL; Anker SD; Bhatt DL; Butler J; Cherney DZI; Claggett BL; Fletcher RA; Herrington WG; Inzucchi SE; Jardine MJ; Mahaffey KW; McGuire DK; McMurray JJV; Neal B; Packer M; Perkovic V; Solomon SD; Staplin N; Vaduganathan M; Wanner C; Wheeler DC; Zannad F; Zhao Y; Heerspink HJL; Sabatine MS; Wiviott SD
Circulation; 2024 Jun; 149(23):1789-1801. PubMed ID: 38583093
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
Diallo A; Carlos-Bolumbu M; Galtier F
Acta Diabetol; 2023 Dec; 60(12):1651-1662. PubMed ID: 37439858
[TBL] [Abstract][Full Text] [Related]
13. Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes - a minireview.
Wieczorek-Surdacka E; Surdacki A; Świerszcz J; Chyrchel B
Folia Med Cracov; 2020; 60(4):97-101. PubMed ID: 33821854
[TBL] [Abstract][Full Text] [Related]
14. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
Dardano A; Miccoli R; Bianchi C; Daniele G; Del Prato S
Diabetes Res Clin Pract; 2020 Apr; 162():108112. PubMed ID: 32198123
[TBL] [Abstract][Full Text] [Related]
15. Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study.
D'Onofrio L; Mignogna C; Carlone A; Bellizzi E; Di Guida M; Moretti C; Zampetti S; Leto G; Maddaloni E; Buzzetti R
Diabetes Res Clin Pract; 2021 Mar; 173():108681. PubMed ID: 33516784
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ
Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
[TBL] [Abstract][Full Text] [Related]
17. Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus.
Zhang J; Van Spall HG; Li L; Khan MS; Pandey A; Thabane L; Bai X; Wang Y; Lip GY; Li G
Diabetes Metab Syndr; 2023 Jul; 17(7):102804. PubMed ID: 37315473
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
[TBL] [Abstract][Full Text] [Related]
19. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
[TBL] [Abstract][Full Text] [Related]
20. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
Neuen BL; Heerspink HJL; Vart P; Claggett BL; Fletcher RA; Arnott C; de Oliveira Costa J; Falster MO; Pearson SA; Mahaffey KW; Neal B; Agarwal R; Bakris G; Perkovic V; Solomon SD; Vaduganathan M
Circulation; 2024 Feb; 149(6):450-462. PubMed ID: 37952217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]